Court Opinion

ID: 9959687
Source: CourtListenerOpinion
Date Created: 2024-04-12 15:01:05.126065+00
Date Added: 2024-06-11T08:18:44.710441
License: Public Domain

Case: 24-1402    Document: 26     Page: 1   Filed: 04/12/2024

           NOTE: This order is nonprecedential.

   United States Court of Appeals
       for the Federal Circuit
                  ______________________

      REGENERON PHARMACEUTICALS, INC.,
              Plaintiff-Appellant

                             v.

    MYLAN PHARMACEUTICALS INC., BIOCON
               BIOLOGICS INC.,
           Defendants-Cross-Appellants

                   AMGEN USA, INC.,
                        Defendant
                  ______________________

                   2024-1402, 2024-1405
                  ______________________

    Appeals from the United States District Court for the
 Northern District of West Virginia in No. 1:22-cv-00061-
 TSK-JPM, Chief Judge Thomas S. Kleeh.
                 ______________________

     Before CHEN, LINN, and HUGHES, Circuit Judges.
 PER CURIAM.
                        ORDER
     Following this court’s February 22, 2024 show cause
 order, the parties agree that the court lacks jurisdiction
 over both the appeal and cross-appeal from the district
 court’s December 27, 2023 decision resolving fewer than all
Case: 24-1402     Document: 26    Page: 2   Filed: 04/12/2024

 2                REGENERON PHARMACEUTICALS, INC. v. MYLAN
                                    PHARMACEUTICALS INC.

 claims at issue. Under the circumstances, we agree and
 conclude that dismissal is appropriate.
     Accordingly,
     IT IS ORDERED THAT:
    (1) Appeal Nos. 2024-1402 and 2024-1405 are dis-
 missed.
     (2) Each party shall bear its own costs.
                                                FOR THE COURT

 April 12, 2024
      Date

 ISSUED AS A MANDATE: April 12, 2024